The FDA has given the green light to Omisirge (omidubicel-onlv), an allogeneic cell therapy derived from modified cord blood, which aims to accelerate the recovery of neutrophils and lower the risk of infection in patients with blood cancers. The treatment is designed for adults and children aged 12 and above ...
Read More »FDA Approves Cell Therapy to Reduce Infection Risk for Blood Cancer Patients after Stem Cell Transplant
